Consensus Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.61 ^USD	-1.23%		-5.85%	+14.18%

May. 23	Atai Life Sciences N.V. Announces Board and Supervisory Board Changes	CI
May. 22	Clarify Pharma confirms name change to File Forge	AN

Evolution of the average Target Price on Atai Life Sciences N.V.

Price target over the last 5 years

History of analyst recommendation changes

873d09778f2d25ab9e144.tHe4AdG1CS1thT-JN3J5Wrb2cgfhYu4Y_UL09h0Jdf8.1yPgLJ3ZTn1fvU3uby09EfWmRWuVKak1ug6sqWtQFJPbGPdut8BsXh3HZg~872c0903c5b1343420051e1a8dc48bf3

Analyst Recommendations on Atai Life Sciences N.V.

Atai Life Sciences Shares Rise Following Maxim Upgrade	Apr. 03	MT
Maxim Upgrades Atai Life Sciences to Buy From Hold, Price Target is $6	Apr. 03	MT
HC Wainwright Cuts Atai Life Sciences Price Target to $15 From $20, Maintains Buy Rating	Apr. 03	MT
Berenberg Bank Adjusts Atai Life Sciences Price Target to $11 From $18, Maintains Buy Rating	23-03-29	MT
Credit Suisse Lowers Atai Life Sciences' PT to $9 From $11, Updates Model After Announced Workforce Reduction; Keeps Outperform Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Atai Life Sciences to $20 From $50, Maintains Buy Rating	23-01-19	MT
EF Hutton Adjusts Atai Life Sciences Price Target to $15 From $23, Maintains Buy Rating	23-01-06	MT
Berenberg Bank Resumes Coverage on Atai Life Sciences With Buy Rating, $18 Price Target	22-12-21	MT
EF Hutton Initiates Atai Life Sciences at Buy With $23 Price Target	22-12-16	MT
Berenberg US CEO Conference	22-11-01	FA
Loop Capital Initiates Atai Life Sciences at Buy With $18 Price Target	22-11-01	MT
Citigroup Adjusts Price Target on Atai Life Sciences to $20 From $22, Reiterates Buy Rating	22-09-01	MT
Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare, Industrial Tech, and Software Sectors	22-07-01	MT
Citigroup Adjusts Price Target on Atai Life Sciences to $22 From $26, Reiterates Buy Rating	22-05-17	MT
RBC Capital Adjusts Atai Life Sciences Price Target to $9 From $12, Maintains Sector Perform - Speculative Risk Rating	22-03-31	MT
Maxim Group Adjusts Atai Life Sciences Price Target to $12 From $25, Maintains Buy Rating	22-02-02	MT
RBC Cuts Price Target on Atai Life Sciences to $12 From $17, Maintains Sector Perform Rating, Speculative Risk Qualifier	22-01-06	MT
Berenberg European Conference	21-12-05	FA
Maxim Group Initiates Coverage on Atai Life Sciences With Buy Rating, $25 Price Target	21-11-30	MT
HC Wainwright Adjusts Atai Life Sciences to $50 From $40, Reiterates Buy Rating	21-11-22	MT
Berenberg Bank Adjusts Atai Life Sciences' Price Target to $38 From $35, Maintains Buy Rating	21-11-17	MT
RBC Trims Price Target on Atai Life Sciences to $17 From $19, Maintains Sector Perform Rating, Speculative Risk Qualifier	21-11-16	MT
Roth Capital Starts Atai Life Sciences at Buy With $32 Price Target	21-11-11	MT
Berenberg US CEO Conference	21-11-08	FA
ATAI LIFE SCIENCES N : HC Wainwright Starts Atai Life Sciences at Buy with $40 Price Target	21-10-18	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.61 USD

Average target price

11.8 USD

Spread / Average Target

+632.92%

High Price Target

21 USD

Spread / Highest target

+1,204.35%

Low Price Target

6 USD

Spread / Lowest Target

+272.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Atai Life Sciences N.V.

Maxim
HC Wainwright
Berenberg Bank
Credit Suisse
EF Hutton
Loop Capital
Citigroup
RBC Capital Markets
Roth Capital Partners
Jefferies & Co.
Canaccord Genuity
Cowen
Cantor Fitzgerald

Ratings for Atai Life Sciences N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar